The name “Aequor” is inspired by the Latin word for “calm waters.” The mission of the company is to provide breakthrough non-toxic, non-inflammatory, and environmentally superior solutions to biofilm-based bacterial contamination in the fields of medicine, sustainable agri/aquaculture, renewable fuels, and food and water safety, as well as solutions to marine and industrial damage related to fouling (the build-up of organic matter on, for example, the hulls of ships, pipelines, underwater structures, etc.). By studying biofilms and fouling in the marine environment since 2001, the Founder of Aequor, Inc. discovered 17 novel marine microbes, including one new genus and three new species. The microbes produce various green chemical compounds, some of which present anti-biofilm, and/or anti-fouling properties. These properties were heretofore undiscovered.
Aequor, Inc. was incorporated in Delaware in 2006. The company has patents pending 17 microorganisms and on their derivatives, methods of extractions, and methods of use in the United States and in countries that are parties to the International Patent Cooperation Treaty. Several of the active chemical agents derived have been reliably and inexpensively reproduced under laboratory conditions. Subsequent research is proving their remarkable properties. The most active agent contains a new chemical, which is the subject of additional patents.
TESTING AND DEVELOPMENT
Nine years of testing in-house and by third parties suggests that Aequor’s active agents are effective and inexpensive to reproduce. Biotechnological usage will be simple. (The scientific explanation for this is that the genotype will probably not revert because the isolated probionts are robust halotolerant microorganisms with a wild-type phenotype.) Research on the microbes at a molecular level in July 2006 at the University of Gutenberg, Sweden and at the Center of Excellence for Regenerative Health Biotechnology (CERHB) in Alachua, Florida through 2010 supported the Founder's findings. The Founder is undertaking prototype R&D at Aequor's lab at 5310 Eastgate Mall, San Diego, California, and in collaboration with strategic partners.
THE BUSINESS MODEL
Aequor seeks to license its patent rights to strategic partners in each target market. Additional revenues will be generated from direct sales, distributor commissions, the sale of registration fees, joint ventures, and grants.
THE TARGET MARKETS
Aequor's platform technologies will be used in multiple horizontal and vertical markets that cumulatively exceed $600 billion annually.
-- Anti-fouling paints and coatings for the hulls and surfaces of all the ships at sea, subsurface marine structures, industrial processes, etc.
-- Water: storage, reverse osmosis filters, pipelines, delivery systems. Fouling requires increased pumping, at higher and higher fuel costs, and the use of harsh chemical decontaminants.
--Sustainable Agriculture, Aquaculture, and Food Safety: Chemical pesticides, biocides, and fungicides applied to reduce production losses cause toxic runoffs that pollute water supplies. The spoilage of fresh and packaged food and beverages across the distribution chain due to biofilm contamination is responsible for further losses. Improving agriculture and aquaculture efficiencies could represent billions of dollars of savings annually, while helping to protect the environment.
--Human and Veterinary Medicine: Microbial biofilms play a central role in human and animal diseases and are often associated with tissues (e.g., chronic wound infections, cystic fibrosis, otitis media, endocarditis, periodontal disease, dental plaque) and infections from in-dwelling medical devices (e.g., catheters, stents, prostheses, transplants). According to the U.S. Centers for Disease Control (CDC), biofilms are associated with approximately 90% of all chronic bacterial infections and 65% of all hospital-acquired infections, costing the U.S. health care system alone over $200 billion per year.